Welcome to the EPA 2021 Interactive Programme
The viewing of sessions and E-Posters cannot be accessed from this conference calendar. All sessions and E-Posters are accessible via the Main Lobby in the virtual platform.
The congress will officially run on Central European Summer Time (CEST)
To convert the congress times to your local time Click Here
Fully Live with Live Q&A On Demand with Live Q&A ECP Session Section Session EPA Course (Pre-Registration Required) Product Theatre
Sessions with Voting Ask the Expert Live TV
EPA 2021 Janssen-sponsored satellite symposium online summary:
This symposium will provide delegates with expert perspectives on optimum schizophrenia management under the challenging conditions of the COVID-19 pandemic. The session will examine considerations for maintenance treatment and long-term care, optimisation of the multidisciplinary team approach to schizophrenia care, and balancing caring for both the mental and physical health of patients with schizophrenia. Topics will include the use of telemedicine in schizophrenia management, recommendations for delivering optimum treatment continuity under social distancing conditions, and the pros and cons of monitoring schizophrenia treatment adherence and outcomes in person as well as through alternative monitoring approaches. In addition, the changes in exposure to antipsychotic medication in patients with schizophrenia during the pandemic will be discussed.
This will be a highly engaging symposium, offering a multitude of fresh perspectives on the current hot topics in schizophrenia management and providing the virtual audience with the opportunity to further benefit from additional insights delivered during our expert faculty discussion.
Educational financial support is provided by Janssen.
The symposium aims to address the broad-spectrum treatment of schizophrenia using the clinical staging framework. In the first lecture the role of partial dopamine agonists in the first episode of psychosis will be uncovered utilizing cariprazine, a third-generation antipsychotic medication as an example. Then, the second lecture will focus on the three R’s in the middle stage of schizophrenia: relapse, remission and recovery, and explain how cariprazine data from clinical trials are linked to these concepts. The final lecture will detail the treatment goals and options in the chronic stage of schizophrenia with special attention to the neurocognitive and negative symptoms and their connection to quality of life and everyday functioning.
Topics for discussion:
1. The unmet need in MDD: importance of rapid treatment and emergency care.
• Overview of the burden of MDD and the challenges in patient management
• The impact of the COVID-19 pandemic.
• Introduce the concept of psychiatric emergencies and the importance of rapid treatment.
2. How can we optimise the management of MDD and TRD?
• Overview of the treatment options for MDD and TRD and in psychiatric emergencies, including new fast-acting treatments.
• How treatment can be optimised for patients with MDD and TRD,
3. Digital care in psychiatry: challenges and opportunities.
• The challenge and rewards of digital approaches within psychiatry, such as virtual consultations or use of smartphone apps in mental healthcare.
• How these may be incorporated into patient care in MDD and TRD.
The focus on adolescent health has been increasing in recent years, with a growing recognition that these years are pivotal in the development and maintenance of health behaviours and outcomes through the life course. Adolescence is a key period for mental health disorder onset, with half of lifetime onset by age. Research over previous decades suggests that the prevalences of mental health problems are increasing in teenagers across different countries. Generally, young patients, particularly those with schizophrenia, may have peculiar needs in terms of treatment, both non-pharmacological and pharmacological. This requires a specific focus on shared decision making, involving patients and caregivers in the treatment process starting from the definition of treatment goals. A proper control of symptoms is essential, nevertheless it is clear that quality of life and functionality should represent a primary target for patients with schizophrenia, caregivers and physicians. A new opportunity for the diagnosis and treatment of schizophrenia in young patients is represented by digital tools. There is a growing field of research that is highlighting the potential effect of digital tools in the whole clinical management of patients, being the young patients particularly keen to the use of digital opportunities. The digital approach already showed to be useful to guarantee a minimum level of care during the COVID pandemic, e.g. telepsychiatry, nevertheless it seems to be a promising option beyond the pandemic because it can promote a patient-centric mindset, empowering patients with schizophrenia and their caregivers.
Major depressive disorder (MDD) is the leading cause of mental health-related disease burden globally, affecting an estimated 300 million people worldwide. MDD is a debilitating condition, with symptoms leading to significant social impairment. Given the prevalence of the condition and the multidimensional nature of MDD, effective treatment leading to full functional recovery is a necessity.
This symposium will highlight hot topics from a clinical perspective, with a focus on symptoms of emotional blunting and anhedonia. In addition, the aspect of trauma in patients with depression will be considered.
Andrea Fagiolini will open the session with an overview of the impact of emotional blunting and lack of motivation on patients with depression, and will present recent evidence on treatments that address these aspects.
Guy Goodwin will further explore the prevalence of emotional blunting in patients with MDD and will describe assessment using the Oxford Depression Questionnaire.
Katherine Shear will consider more broadly the topic of psychological trauma, with a particular focus on traumatic grief.
Andrea Fagiolini will conclude with presentation of recent data on the treatment of the sub-population of patients with depression who have a history of psychological trauma.
The session will be followed by a question-and-answer panel discussion, during which your active participation is encouraged.
The product theatre aims to provide further understanding of the effectiveness and safety of cariprazine, a novel D3-D2 partial dopamine agonist. While novel medications are the driving force of improved treatment and eventually better life for patients, there is in general a bit of fear of trying out new drugs. To alleviate these fears, professor Göran Hajak will provide some insight in how to use cariprazine in the clinic, explain the rationale behind the clinical decisions to prescribe cariprazine and bring a few cases to illustrate the process.
Importance of treatment adherence in schizophrenia, Benefits of early intervention in schizophrenia, Early intervention with Long Acting Injectables, Restoring function in schizophrenia, and Two injection start initiation regimen for Aripiprazole Once Monthly 400mg.